Bifidobacterium is one of many probiotic bacteria that has a series of useful functions, such as improving digestion, accelerating the immune system, and resisting their pathogenic cousins.
Bifidobacterium is a genus of Gram-positive, nonpathogenic, nonmobile, frequently branched anaerobic bacteria. Bifidobacterium spp. are sometimes arranged in pairs, in a "V" shape, in chains, and the palisade of parallel cells or garlands. They are ubiquitous inhabitants of the gastrointestinal (GI) tract, vagina, and mouth of mammals, including humans. The genus Bifidobacterium is the third-largest bacterial population in the GI tract of mammals after Bacteroides and Eubacterium. Bifidobacterium spp. are considered probiotic microorganisms because they provide a variety of health benefits for human hosts, including improvement of lactose utilization, improved animal host immunity, and antagonism effect against pathogenic bacteria.
Bifidobacterium spp. are the normal host of the healthy human intestinal tract. They can regulate some important metabolic and physiological functions of the host, promote the maturation of the immune system in early life, and contribute to its homeostasis during life. Alterations in gut microbiota can occur through changes in composition (dysbiosis), function, or the interaction between the microbiota and the host. Changes in the number and composition of the intestinal microbiota are one of the most common characteristics of many diseases. The use of probiotics, including Bifidobacterium spp., in preventive medicine to maintain healthy intestinal function is well documented.
The beneficial effects of B. breve have been reported in the treatment of many different levels of human diseases. These diseases include GI disorders, metabolic disease, skin disease, neurologic/psychiatric disorders, and so on.
B. longum can help the body resist harmful bacteria against intestinal or intestinal pathogens, thus providing benefits for the treatment of some diseases, including GI disorders, celiac diseases, cancer, and autoimmune disease.
Currently, probiotic preparations containing Bifidobacterium spp., used alone or in combination with other bacteria, have been tested in human clinical studies. Despite a large amount of literature and research on this topic, in most cases, there is still insufficient scientific evidence for the effectiveness of probiotics. More effort is required to design and conduct accurate human studies to prove the efficacy of probiotics in preventing, relieving, or treating different pathologies.
Relying on years of professional knowledge and project experience accumulated in the field of drug development and bacteria, Creative Biolabs has launched a comprehensive and reliable Bifidobacterium drug development service. We are committed to rationally designing research programs, fully considering the pros and cons of each type of probiotics, to contribute to human health.
For Research Use Only. Not intended for use in food manufacturing or medical procedures (diagnostics or therapeutics). Do Not Use in Humans.